Cost-utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency.

Published in: Vox sanguinis (2019)

For SID patients in Queensland (Australia), the home-based SCIg treatment option provides better health outcomes and cost savings.

Keyphrases